These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22429537)

  • 1. Vitreomacular traction in a case of exudative age-related macular degeneration resistant to anti-VEGF therapy.
    Shah SU; Haller JA
    Acta Ophthalmol; 2012 Nov; 90(7):e569-70. PubMed ID: 22429537
    [No Abstract]   [Full Text] [Related]  

  • 2. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectral domain optical coherence tomography for higher precision in the evaluation of vitreoretinal adhesions in exudative age-related macular degeneration.
    Krebs I; Glittenberg C; Zeiler F; Binder S
    Br J Ophthalmol; 2011 Oct; 95(10):1415-8. PubMed ID: 21270433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX).
    Houston SK; Rayess N; Cohen MN; Ho AC; Regillo CD
    Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy.
    Golbaz I; Ahlers C; Stock G; Schütze C; Schriefl S; Schlanitz F; Simader C; Prünte C; Schmidt-Erfurth UM
    Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1599-605. PubMed ID: 21051733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystoid macular degeneration in exudative age-related macular degeneration.
    Querques G; Coscas F; Forte R; Massamba N; Sterkers M; Souied EH
    Am J Ophthalmol; 2011 Jul; 152(1):100-107.e2. PubMed ID: 21570056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neovascular AMD with marked macular fluid and rapid response to anti-VEGF therapy.
    Wood E; Chang JS; Flynn HW; Kitchens JW
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(2):175-8. PubMed ID: 24512809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
    Gomi F; Sawa M; Tsujikawa M; Nishida K
    Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pearl necklace sign: a novel spectral domain optical coherence tomography finding in exudative macular disease.
    Gelman SK; Freund KB; Shah VP; Sarraf D
    Retina; 2014 Oct; 34(10):2088-95. PubMed ID: 25020214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor treatment in age-related macular degeneration.
    Üney GÖ; Ünlü N; Acar MA; Hazirolan D; Altiparmak UE; Yalniz-Akkaya Z; Örnek F
    Retina; 2014 Jan; 34(1):32-7. PubMed ID: 23751943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration.
    Rauch R; Weingessel B; Maca SM; Vecsei-Marlovits PV
    Retina; 2012 Jul; 32(7):1260-4. PubMed ID: 22186738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Responses to ranibizumab in wet age-related macular degeneration patients with vitreomacular traction].
    Filloy A; Arias L
    Arch Soc Esp Oftalmol; 2013 Oct; 88(10):380-6. PubMed ID: 24060301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
    Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
    Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
    Park SS; Daftari I; Phillips T; Morse LS
    Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of wet age-related macular degeneration by ranibizumab in "real life" in France: treatment behaviours and associated visual outcome.
    Souied EH; Cohen SY; de Pouvourville G; Dupeyron G; Latour E; Ponthieux A; Weber M
    Acta Ophthalmol; 2015 Mar; 93(2):e179-80. PubMed ID: 25377519
    [No Abstract]   [Full Text] [Related]  

  • 17. Circulating antiretinal antibodies predict the outcome of anti-VEGF therapy in patients with exudative age-related macular degeneration.
    Kubicka-Trząska A; Wilańska J; Romanowska-Dixon B; Sanak M
    Acta Ophthalmol; 2012 Feb; 90(1):e21-4. PubMed ID: 21883989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth of type 1 neovascularization following cessation of anti-vascular endothelial growth factor therapy as a possible explanation for treatment resistance.
    Shah VP; Freund KB
    JAMA Ophthalmol; 2013 Jul; 131(7):967-9. PubMed ID: 23846209
    [No Abstract]   [Full Text] [Related]  

  • 19. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
    Donahue SP; Recchia F; Sternberg P
    Am J Ophthalmol; 2010 Aug; 150(2):287; author reply 287. PubMed ID: 20670740
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of vitrectomy and inner limiting membrane peeling in age-related macular degeneration resistant to anti-vascular endothelial growth factor therapy, with vitreomacular traction or epiretinal membrane.
    Kimura S; Morizane Y; Toshima S; Hosogi M; Kumase F; Hosokawa M; Shiode Y; Fujiwara A; Shiraga F
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1731-6. PubMed ID: 26951250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.